Adding docetaxel to androgen deprivation therapy (ADT) plus radiation therapy (RT) failed to improve survival in unfavorable-risk prostate cancer, though the combination may hold benefit for certain ...

Chemotherapy sequencing in the ARPI era and the role of radiopharmaceuticals versus docetaxel remain unsettled, while ...

Pembrolizumab plus docetaxel does not improve radiographic progression-free survival or overall survival compared with docetaxel alone. Adding pembrolizumab to docetaxel is not better than docetaxel ...

Please provide your email address to receive an email when new articles are posted on . Men with metastatic castration-resistant prostate cancer had significantly longer OS with docetaxel rechallenge ...

Shares in CRISM Therapeutics rose 19% to 14p on Tuesday after the AIM-quoted drug delivery company reported positive ...

Doxetaxel recharge was associated with a 3.3-month benefit in OS and a 1.8-month improvement in time to subsequent treatment or death. Docetaxel rechallenge improved overall survival compared with ...

Objective: To assess the efficacy and safety profile of docetaxel, as a single agent, in the treatment of elderly patients with advanced breast cancer. Methods: Twenty-eight patients, with a median ...

Please provide your email address to receive an email when new articles are posted on . The addition of docetaxel to cisplatin and 5-FU chemotherapy significantly extended OS as neoadjuvant therapy ...

A partitioned-survival lifetime model (2025 USD) compared ADT alone with seven intensification strategies across PFS, post-progression, and death, using published survival curves and literature-based ...

Docetaxel rechallenge was tied to improved overall survival compared with cabazitaxel in men with metastatic castration-resistant prostate cancer (mCRPC) who did not experience disease progression on ...